Biocytogen Pharmaceuticals Beijing (2315) H2 2024 earnings summary

Executive summary

• FY24 revenue rose 36.8% to RMB980.5m; net profit was RMB33.5m versus a RMB383.0m loss in FY23, with operating cash flow turning positive at RMB211.2m.

• Management linked the turnaround to stronger animal model and antibody development sales, lower R&D and administrative expenses, and operational efficiency measures.

Financial highlights

• Revenue increased 36.8% to RMB980.5m; gross profit rose 50.5% to RMB761.5m, while cost of sales grew 3.8% to RMB218.9m.

• Profit before tax was RMB42.9m versus a FY23 loss of RMB380.2m; net income was RMB33.5m versus a loss of RMB383.0m.

• Net cash from operating activities was RMB211.2m versus RMB76.6m used in FY23; cash and cash equivalents at year-end were RMB384.5m versus RMB399.6m.

Outlook and guidance

• For 2025, management expects rapid operating income growth and further profitability expansion toward scalable profits, supported by internally generated capital.

• Plans include integrating AI into antibody discovery, investing in preclinical products and services, expanding overseas operations, and maintaining high gross margins while controlling costs.

• Potential collaboration agreements for YH016 and YH017 are being pursued, with agreements expected by end-2025.